October 15th, 2025 | 08:35 CEST
BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!
The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?
time to read: 3 minutes | Author: Fabian Lorenz
ISIN: PLUG POWER INC. DL-_01 | US72919P2020 , GERRESHEIMER AG | DE000A0LD6E6 , NETRAMARK HOLDINGS INC | CA64119M1059
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
NetraMark Holdings: New data for the fight against cancer
Has the correction in NetraMark shares ended? Could now be the time to buy? Yesterday, the shares of this AI hidden gem traded favorably in an otherwise weak market environment. After a price slide of around 30% over a few weeks, this seems overdue. NetraMark's AI platform, NetraAI, supports pharmaceutical and biotech companies in conducting clinical trials. Its goal is to reduce costs for clients while increasing the probability of success in drug development. This should make it one of the winners of the development in the US. The Trump administration appears to be serious about reducing drug prices in the world's most important pharmaceutical market. The resulting pressure on industry to reduce development costs could benefit NetraMark. Analysts at Zacks Small Cap Research see the fair value of the stock at CAD 2.25. The security is currently trading at CAD 1.34 and is also available on platforms like Tradegate.
In recent months, several customers and collaboration partners, such as CRO Worldwide Clinical Trials and Asklepion Pharmaceuticals, have already been reported. Most recently, an exciting partnership in the field of glioblastoma (GBM) research was reported. Glioblastoma is an aggressive and difficult-to-treat form of cancer, with a five-year survival rate of less than 7%. At the same time, clinical trials of potential drugs for GBM face a failure rate of over 90%.
https://youtu.be/Rg_Zn7lctTk?si=Cul1mpqqgrzJMgQZ
NetraMark sees the collaboration as an opportunity to design more efficient, targeted, and successful glioblastoma studies. To this end, a leading medical research center in the US is granting NetraAI access to its wealth of data. The data will be used to identify patient subgroups and thus develop a tool to support therapeutic decision-making. Such historical data form the foundation for training successful AI. Accordingly, the collaboration is expected to provide a significant boost to NetraAI's capabilities.
Plug Power: Time to take profits?
There has been no sign of a correction at Plug Power so far. Yet profit-taking would be understandable after a rally of around 270% within six months. Even the surprise announcement that CEO Andy Marsh will be stepping down after 18 years with the Company only caused a brief blip in the share price. Investors continue to bet that hydrogen will also benefit from the energy demands of the AI era.
Even an analyst downgrade has not affected the share price so far. Clear Street has downgraded Plug Power's stock from "Buy" to "Hold." The price target remains at USD 3.50. However, the stock is currently trading at USD 3.83.
Analysts continue to view the Company as on track for long-term success. The potential linked to supplying energy to data centers is evident. However, significant revenues are not expected before 2026. Although analysts foresee rising sales in the coming years, the break-even point is not yet in sight. Therefore, they see a further need for financing and consider the stock to be fairly valued.
Gerresheimer: Analysts divided
The fair value of Gerresheimer shares is currently being radically reduced by analysts. However, given the share price slump from over EUR 100 to below EUR 30 within the last 12 months, this comes a little late.
Most recently, UBS cut its price target for the specialty packaging manufacturer's stock from EUR 75 to EUR 29. Consequently, the rating was adjusted from "Buy" to "Neutral." Following the price target reduction from EUR 37 to EUR 25, DZ Bank even recommends selling. JPMorgan remains one of the few Gerresheimer bulls. There, too, the price target was slashed from EUR 99.30. At EUR 46, however, the fair value is still seen as above the current level, and the recommendation is "Overweight." For JPMorgan, the price slump following the recent profit warning was excessive. While the loss of confidence is understandable, the current risk/reward ratio appears attractive.
NetraMark shares currently appear to offer an exciting entry opportunity. The recent collaboration and the valuable data gained to strengthen its AI are not yet reflected in the share price. This is likely to change soon. Consolidation does indeed seem appropriate for Plug Power, as there is still a long way to go before it returns to profitability. At Gerresheimer, the loss of confidence is significant, but for brave investors, the current situation could present a buying opportunity.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
